Nov 11, 2009 (Datamonitor via COMTEX) -- Cerimon Pharmaceuticals, a biopharmaceutical company, has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the EU, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed.

Cerimon initially acquired the US rights to develop and commercialize the patch formulation of diclofenac in 2005. Cerimon also announced that it recently received notification from the US Patent and Trademark Office allowing patent claims covering its diclofenac patch.

Cerimon has also completed enrollment in its Phase III program evaluating the company's diclofenac patch for the treatment of acute pain.

Cerimon's Phase III program consists of three, multi-center, randomized, double-blind, placebo-controlled studies of over 800 patients with acute pain caused by mild-to-moderate ankle sprains, wrist injuries and soft tissue injuries of the upper and lower extremities, respectively. The studies are designed to assess the safety and efficacy of Cerimon's diclofenac patch compared to placebo.

James Shannon, CEO of Cerimon, said: "There is a growing physician and patient interest in prescription therapies that can deliver safe, effective and convenient site-specific pain management. We believe our patch will be able to address this interest, and by acquiring the European rights to our diclofenac patch, we hope to bring safe and effective pain relief to a greater patient population."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon